FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news